06.01.2023 13:50:44
|
Alvotech : FDA Accepts BLA For AVT04, Proposed Biosimilar To Stelara
(RTTNews) - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), said that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech's proposed biosimilar to Stelara (ustekinumab), which is prescribed to treat a variety of inflammatory conditions.
The companies anticipate that the FDA's review will be completed in second half of 2023.
AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses. AVT04 is an investigational product and has not received regulatory approval in any country.
For More Such Health News, visit rttnews.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alvotech Registered Shsmehr Nachrichten
12.11.24 |
Ausblick: Alvotech Registered stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
29.10.24 |
Erste Schätzungen: Alvotech Registered veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) |
Analysen zu Alvotech Registered Shsmehr Analysen
Aktien in diesem Artikel
Alvotech Registered Shs | 13,05 | 0,38% | |
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 19,85 | -2,70% |